Study to Evaluate the Adjunctive Effect of CreNeuroS™ CNS Fish Oil Plus Softgels in Patients With Major Depressive Disorder Receiving Escitalopram.

Ki vehet részt

• Male or female subjects aged between 18 and 65 years, inclusive
• Subjects with a clinical diagnosis of Major Depressive Disorder (MDD) as determined by the investigator or qualified psychiatrist, based on standard clinical judgment
• Subjects with moderate to severe depression, defined as a Hamilton Depression Rating Scale (HAM-D-17) score ≥18 at both screening and baseline visits
• Subjects who are either:; Planned to initiate treatment with escitalopram, or; Have already started escitalopram therapy within ≤2 weeks prior to screening, provided that any prior antidepressant therapy was discontinued with an adequate washout period (≥2 weeks or ≥5 half-lives of the previous medication, whichever is longer) before baseline assessment
• Subjects who are medically stable, as assessed by the investigator based on medical history, physical examination, and any relevant laboratory investigations
• Subjects who are able and willing to provide written informed consent prior to participation in the study
• Subjects who are willing and able to comply with study procedures, treatment regimen, and scheduled study visits

Ki nem vehet részt

• Use of concomitant medications or treatments that may confound study outcomes, including:; Other antidepressants (unless in the process of being switched to escitalopram); use of omega-3 or fish oil or folic acid, or L-5-methyltetrahydrofolate supplements
• History of substance abuse within 6 months prior to screening
• Prior treatment with electroconvulsive therapy (ECT), transcranial magnetic stimulation (TMS), vagus nerve stimulation (VNS), or deep brain stimulation (DBS) during the current depressive episode
• Initiation of new psychotherapy or change in psychotherapy intensity within 8 weeks prior to screening
• Participation in other interventional or non-interventional studies within 3 months prior to screening
• High suicide risk, defined as:; Presence of active suicidal ideation with intent or plan, or; Subject considered by the investigator to be at significant risk of suicide; History of suicide attempt or self-harm
• Presence of major psychiatric disorders other than MDD, including but not limited to:; Bipolar disorder; Schizophrenia or other psychotic disorders
• Presence of severe or unstable medical conditions that may interfere with study participation or pose a risk to the subject, including but not limited to:; Uncontrolled hepatic (liver) disease; Significant renal (kidney) impairment; Clinically significant cardiovascular disease
• Known hypersensitivity or allergy to:; Escitalopram; Fish oil or omega-3 fatty acid or folic acid, or L-5-methyltetrahydrofolate supplements
• Any condition or circumstance which, in the opinion of the investigator, may compromise subject safety, adherence to study procedures, or the integrity of study data
• Moderate to severe anxiety disorders, as assessed by GAD-7
• Pregnant or lactating women, or women planning to become pregnant during the study period
• High dietary intake of fish (≥3 times per week) or use of fish oil/n-3 PUFA/folate supplements within the past 6 months
• Participation in another clinical study within 30 days